We report the practical synthesis and structural characterization of a set of conformationally constrained protected arginine analogues. These enantiomerically pure analogues have the general structure 1 and are prepared in seven to eight steps from the commercially available isomers of 4-hydroxyproline. These analogues vary in side chain length and in relative and absolute stereochemistry and are suitable for the direct introduction into peptides. The resulting peptide analogues should be useful as enzymatically stable replacements for bioactive peptides and as probes for understanding the conformational aspects of protein-peptide interactions.
EP300/CREBBP INHIBITOR
申请人:Daiichi Sankyo Company, Limited
公开号:US20210171520A1
公开(公告)日:2021-06-10
The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof:
wherein ring Q
1
, ring Q
2
, R
1
, R
2
, R
3
and R
4
respectively have the same meanings as defined in the specification.
Discovery of EP300/CBP histone acetyltransferase inhibitors through scaffold hopping of 1,4-oxazepane ring
EP300 and its paralog CBP play an important role in post-translational modification as histoneacetyltransferases (HATs). EP300/CBP inhibition has been gaining attention as an anticancer treatment target in recent years. Herein, we describe the identification of a novel, highly selective EP300/CBPinhibitor, compound 11 (DS17701585), by scaffold hopping and structure-based optimization of a high-throughput